CNBC’s UK Exchange Newsletter: Dependent on Rebates?

CNBC's UK Exchange Newsletter: Dependent on Rebates?

Industry Insight

When considering the UK's leading sectors, the life sciences industry often comes to mind for many professionals.

The UK is home to two pharmaceutical giants among the world's top 15, a distinction shared only with the US and Switzerland. In addition, the universities of Cambridge, Oxford, and Imperial College London are recognized among the global leaders in life sciences academia.

However, beneath this surface-level success, tensions are rising. Recent conflicts over drug pricing have strained the relationship between the British government and the pharmaceuticals sector. This sector includes leading multinational firms such as Pfizer, Sanofi, Merck, Eli Lilly, and Bristol-Myers Squibb, in addition to domestic companies like AstraZeneca (AZ) and GlaxoSmithKline (GSK).

NHS and Pharmaceutical Pricing Agreements

In the UK, the National Health Service (NHS), funded by the state, purchases the majority of branded medications. The NHS's substantial purchasing power derives from comprising about 85% of the nation's health expenditures.

This power has long been stabilized through voluntary pricing agreements with the pharmaceuticals industry. One such agreement is the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), which came into effect at the start of last year.

The VPAG sets an annual expenditure limit by the NHS on branded medicines, beginning with an allowed increase of 2% per year, rising to 4% by 2027. Pharmaceutical companies agree to refund part of their earnings through rebates to stay within this limit. Shockwaves were felt in December when Health Secretary Wes Streeting announced an unexpected rebate rate of 23%, a sharp rise surpassing the anticipated 15%.

Repercussions of Increased Rebate Rates

The Association of the British Pharmaceutical Industry (ABPI) raised concerns about the severe impact this heightened rate would have on industry growth and investment within the UK. They underscored that the NHS allocates a smaller proportion of its budget to pharmaceuticals—9%—compared to equivalent nations like France and Germany, where the percentages stand higher.

Following this, negotiations have continued, yet were recently halted after the ABPI dismissed a proposal from Streeting, which promised reduced future rebate rates and higher pricing on new medications.

Streeting firmly responded, asserting that he wouldn't allow major pharmaceutical companies to exploit patients or taxpayers.

Pharmaceuticals: Threats to the UK Economy

There is a looming danger that this discord may have broader economic implications, especially as Streeting is seen as a potential successor to the current Prime Minister. Discord has already impacted relations with AstraZeneca, led by CEO Pascal Soriot, who plans to invest heavily in the American market by 2030.

Other pharma executives, such as Pfizer's John McGinley and Merck’s Doina Ionescu, have also voiced their concerns. They critiqued the revised rebate rates as financially untenable, arguing that it challenges the UK's strong standing in the global life sciences arena.

Novartis' Johan Kahlström added that these developments have rendered the UK less desirable for further pharmaceutical investments.

Adding to the complexity is the external pressure from the U.S. administration, which seeks to reduce domestic drug prices and align them with rates found in Europe and Canada. This international pricing contention pressures companies to negotiate more advantageous deals with the UK, despite uncertainty over potential tariffs affecting pharmaceutical imports.

In addition, this situation might incentivize firms like AstraZeneca to redirect their research expenditures to the United States, where the government has urged for increased investment.

Future Pathways for UK Pharmaceuticals

Potentially compounding the problem is the timing of new drug releases in the UK, impeded by strict assessment criteria employed by the National Institute for Health and Care Excellence (NICE). The UK government, despite its pledge to transform the nation into a 'life sciences superpower,' now finds itself in a challenging situation.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts